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lion individuals worldwide [1,2]. Among those exposed to HCV,
between 50% and 80% develop chronic infection that may result
in progressive liver ﬁbrosis and consequently in cirrhosis and/
or hepatocellular carcinoma. Among HIV-infected people,
approximately 15–30% are co-infected with HCV, and the hepati-
tis virus is a leading cause of death in these individuals [3,4].
Unfortunately, therapeutic efﬁcacy is diminished in HIV/HCV
co-infected compared to HCV mono-infected patients to current
standard therapy, which consists of pegylated-interferon (PEG-
IFN) and ribavirin (RBV) [3]. Two separate formulations of PEG-
IFN have been approved, alfa-2a and alfa-2b, each with different
pharmacokinetic proﬁles [5], and these medications are typically
administered for 48 weeks. They can be difﬁcult to tolerate; con-
sequently, therapy in those unlikely to respond should be limited.
According to current guidelines, patients should be treated for at
least 12 weeks to determine whether a 2-log HCV RNA decline
has occurred, thereby justifying treatment continuation [6]. How-
ever, the identiﬁcation of parameters that could be used earlier
for therapeutic intervention would be of tremendous importance.
Successful treatment outcome for HCV in PEG-IFN/RBV treated
patients has been deﬁned as undetectable HCV RNA in serum
6 months after the end of treatment (sustained virological
response [SVR]). Nonresponders (NR) are those in whom serum
HCV RNA is detectable 6 months post treatment cessation. SVR
occurs in 27–40% of HIV/HCV coinfected treated patients [3].
Mathematical modeling of HCV RNA decay has been used to
assess the effectiveness of anti-HCV treatment [7,8]. Early viral
dynamic models that used standard IFN alfa assumed constant
effectiveness, which was appropriate when IFN was administered
thrice weekly. In contrast, when patients were treated with PEG-
IFN alfa-2b, time-varying IFN concentration was observed [9]. To
account for these changes, Powers et al. incorporated pharmaco-
kinetic/pharmacodynamic parameters into a viral dynamic modelJournal of Hepatology 20
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nonresponder; PK, pharmacokinetics; PD, pharmacodynamics.[10]. Pharmacokinetics (PK) establishes the connection between
drug inﬂow and concentration in blood and includes parameters
such as drug absorption, elimination, and blood volume. Pharma-
codynamics (PD) establishes the connection between drug con-
centration and clinical outcome. PK/PD of PEG-IFN/RBV has
been modeled through partial differential equations constructed
to explain the drug’s mechanism of action [11]. Using mechanis-
tic models, one can estimate in vivo parameters that are not
directly measurable, such as how effective a drug (i.e., IFN) is in
blocking virus production, or to make inferences about other clin-
ically-useful variables, such as the duration of treatment neces-
sary to eradicate the virus [12,13]. Limitations of the
mechanistic models include difﬁculty in model validation as well
as computational issues that may arise due to the approximating
and iterative nature of the algorithms used to estimate the
parameters and their convergence.
An important question is whether PK/PD properties of PEG-
IFN/RBV can identify HCV-infected patients early in treatment
who are unlikely to respond. To address this issue, we con-
structed a dynamic model that incorporates PK/PD parameters
and applied it to data obtained from 24 HIV/HCV co-infected
patients treated with PEG-IFN alfa-2b/RBV [14]. We found that
EC50, the median individual effective concentration of PEG-IFN,
was signiﬁcantly lower in SVR compared with NR patients. Addi-
tionally, the estimated PK parameters did not differ signiﬁcantly
between the two patient groups.
Recent studies also evaluated the utility of PK/PD parameters
for their ability to identify NR patients early in therapy [15–17].
Rozenberg et al. evaluated PK/PD and viral parameters and their
association with treatment outcome in 23 HIV/HCV co-infected
patients treated with PEG-IFN alfa-2b. These investigators addi-
tionally studied whether PK/PD parameters differ between Afri-
can Americans and Caucasians and found that the EC50 was
signiﬁcantly lower in Caucasians. Moreover, patients who
achieved an SVR maintained serum concentrations of IFN above
the EC90, an improved estimator of antiviral sensitivity than
EC50, for longer periods of time than NR patients.
In comparison to the above-referenced studies that investi-
gated PK/PD properties of PEG-IFN alfa-2b in co-infected patients
[14,15], in the current issue of the Journal of Hepatology, Dahari
et al. performed a comprehensive analysis of PK/PD of PEG-IFN
alfa-2a in 26 co-infected patients [18]. This analysis is particu-10 vol. 53 j 418–420
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larly important because of the differences in pharmacokinetics
between the two PEG-IFN preparations and, in addition, their
decreased therapeutic efﬁcacy in co-infected patients. Dahari
et al. used mathematical models together with two-stage, indi-
vidual-based, nonlinear least squares method to estimate the
PK/PD parameters associated with PEG-IFN. Their main purpose
was to discover PK/PD-related parameters that could be used to
identify potential NR patients. PEG-IFN concentration and HCV
RNA levels were sampled frequently until week 12. Five of the
26 patients were excluded from the modeling due to early treat-
ment discontinuation. The authors estimated the PK parameters
for the ﬁrst week and for the twelfth week of treatment. They also
estimated the maximum PEG-IFN effectiveness during the ﬁrst
dose, e7max, and the infected cell loss rate, d, for each patient.
Then, they used nonparametric statistical methods to compare
the estimated quantities between SVR and NR, between HCV
genotypes 1 and 3, and between African Americans and Cauca-
sians. The authors identiﬁed and described four viral kinetic pat-
terns. In patients with a triphasic HCV RNA decay pattern, they ﬁt
the combined-PD model that includes additional terms for hepa-
tocyte proliferation. In patients with a biphasic decline, they ﬁt
the combined biphasic-PD model.
Based on their results, Dahari et al. conclude that none of the
PK parameters can signiﬁcantly differentiate between NR and
SVR. However, they identiﬁed two PD parameters with 100%
positive predictive value for the identiﬁcation of SVR patients:
(1) the maximum PEG-IFN effectiveness during the ﬁrst dose,
e7max, and (2) the infected cell loss rate, d. When comparing the
PK/PD parameters between individuals infected with HCV geno-
types 1 and 3; these authors concluded that EC50 is signiﬁcantly
lower, and that d is signiﬁcantly increased in genotype 3-infected
individuals. In addition, they did not identify signiﬁcant differ-
ences in the viral kinetic and pharmacodynamic parameters
between Caucasians and African Americans.
An important issue is the statistical technique used in the
analysis of PK/PD data. In general, two statistical approaches,
the two-stage nonlinear least squares approach (individual PK),
and the nonlinear mixed effects model (population PK) (Table 1)
have been established for the analysis of PK/PD data. Brieﬂy, the
two-stage (individual PK) approach requires that a large number
of observations are obtained for each patient at the same time
points in order to obtain parameter estimates. The ﬁrst stage of
this procedure consists of using nonlinear regression (nonlinear
least squares) to estimate the PK/PD parameters for each individ-
ual separately. In the second stage, these parameters are summa-
rized through computation of descriptive statistics (means,
variances), and a subsequent analysis of dependencies between
the estimated parameters and patient-related covariates can be
performed. The three studies discussed above [14,15,18] usedTable 1. Summary of the characteristics of the population (nonlinear m
(nonlinear least squares method) pharmacokinetic approach.
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Journal of Hepatology 201this statistical technique. An alternative approach for analysis
of PK/PD data is based on the nonlinear mixed effects models.
This method is especially appropriate in sparse or unbalanced
data situations (i.e., patients may have different sampling times
or may have missed some measurements) and when the investi-
gator is interested in making generalizations about the popula-
tion from which the study subjects were randomly selected. In
contrast to the two-stage approach, in this procedure the popula-
tion parameters are estimated directly, and inter and intra-sub-
ject variability is incorporated into the model. As the presence
of missing values is a common problem in studies of HCV-
infected persons because of poor compliance among some HCV-
infected populations, the population PK approach may be a useful
tool for analyzing such data. The US Food and Drug Administra-
tion has issued guidelines concerning the use of population PK
in the process of drug development [19].
In conclusion, identifying PK/PD models that describe the
relationship between the concentration of the drug in the
blood, the dose of the drug, other PK parameters and covariates
is a very important aspect in the area of HCV therapeutics.
Besides IFN, exploring differences in RBV pharmacokinetics, as
has been done in various studies [17,20], and the PK/PD of
directly acting antivirals, are additional considerations that
may differentiate SVR and NR patients. Explaining inter and
intra-subject variability in the PK of a drug, or in viral kinetics,
is a central goal of the analysis of PK/PD parameters. Studies
investigating the mechanism of action of IFN performed to date
have not identiﬁed PK parameters that signiﬁcantly differ
between SVR and NR patients. In contrast, some PD parameters
have been identiﬁed with the ability to differentiate between
these two patient groups. Dahari et al. investigated the impor-
tant problem of modeling the pharmacokinetics of PEG-IFN
alfa-2a and the HCV viral kinetics in HIV/HCV co-infected
patients, which is motivated by the widespread use of PEG-
IFN alfa-2a in clinical practice. The investigators found that
the maximum PEG-IFN effectiveness during the ﬁrst dose,
and the infected cell loss rate can differentiate SVR from NR
patients. Further research is needed to conﬁrm the ﬁndings
concerning the use of viral kinetic parameters as prognostic
tools of treatment outcome and to determine their role in
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